Indications and Usage:

Insudive is indicated for use in adult patients with type 2 diabetes mellitus in addition to the diet and exercise to improve glycemic control as: 

• monotherapy; 
• combination therapy with other oral hypoglycemic agents (OHPs) – metformin, metformin and sulfonylurea derivatives, metformin and/or thiazolidinediones, in patients who have not achieved adequate glycemic control with previous therapy; 
• combination therapy with insulin in patients who have not achieved adequate glycemic control on therapy with semaglutide and metformin.

Insudive is indicated to reduce the risk of major cardiovascular events in patients with type 2 diabetes mellitus and high cardiovascular risk as an adjunct to standard cardiovascular treatment (based on analysis of time to first major cardiovascular event).

*Major cardiovascular events include: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke.

This product is included in the Essential Drug List (EDL).

Regulatory Status: Rx only.

THERE ARE CONTRAINDICATIONS AND DRUG INTERACTIONS. PLEASE CONSULT A SPECIALIST BEFORE USE.

For the full version of the Insudive (semaglutide) leaflet, please visit this website: https://grls.rosminzdrav.ru/Default.aspx